Erasca Inc (ERAS) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. The Company’s pipeline includes five clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, a SHP2 inhibitor, an EGFR inhibitor, and a central nervous system (CNS)-penetrant KRAS G12C inhibitor, and seven discovery-stage programs targeting other key oncogenic drivers. The Company’s lead product candidate is naporafenib, designed to be a reversible, potent and selective ATP-competitive type 2 pan-RAF kinase inhibitor.
Contact details
Important dates
General stock information
- Short code:
- ERAS
- ISIN:
- US29479A1088
- Market cap:
- $334.54 million
- Shares in issue:
- 173.34 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.